USPTO Examiner PHAM KATHERINE PH MINH - Art Unit 3781

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18674694Urinary Drainage System with Air Pressure ApparatusMay 2024June 2025Allow1310NoNo
18641163SYSTEMS AND METHODS FOR EXTENDING OPERATIONAL TIME OF NEGATIVE PRESSURE WOUND TREATMENT APPARATUSESApril 2024May 2025Allow1300YesNo
18477633VARIABLE PARTICLE SIZE TISSUE COLLECTORDecember 2023June 2025Allow2130NoNo
18190902CATHETER SYSTEMS AND METHODS FOR MEDICAL PROCEDURES USING CATHETERSMarch 2023February 2026Allow3511NoNo
17998981A MOBILE NEGATIVE PRESSURE WOUND THERAPY DEVICENovember 2022February 2025Allow2740YesNo
17919316MULTI-VIAL CONNECTOROctober 2022December 2025Abandon3810NoNo
17889423Devices for shunting bloodAugust 2022February 2026Allow4231YesNo
17867918Female Urine Specimen KitJuly 2022February 2025Abandon3130NoNo
17792065SYSTEMS AND METHODS FOR MONITORING OPERATIONAL LIFETIME OF NEGATIVE PRESSURE WOUND TREATMENT APPARATUSESJuly 2022January 2026Allow4230YesNo
17791329SYSTEMS AND METHODS FOR CONTROLLING FLUID INSTILLATION THERAPY USING PH FEEDBACKJuly 2022September 2025Allow3920NoNo
17748350KIDNEY STONE SUCTION TUBE DEVICE AND RELATED METHODS OF USEMay 2022June 2025Allow3720YesNo
17745258BLOOD ANALYSIS SYSTEMMay 2022June 2025Abandon3710NoNo
17730590Snag Resistant Blood Absorbence Pad And Method For Use By A Patient Having BracesApril 2022July 2024Abandon2740NoNo
17657992METHODS OF TREATING A VESSEL USING AN ASPIRATION PATTERNApril 2022October 2025Allow4210YesNo
17700328Absorbent Hygienic Article Having an Integrated Drainage MechanismMarch 2022October 2023Abandon1910NoNo
17679283OXYGENATOR WITH PRESSURE RELIEF AND SAMPLINGFebruary 2022February 2025Allow3610NoNo
17645821MALE EXTERNAL CATHETER WITH ATTACHMENT INTERFACE CONFIGURED TO BIAS AGAINST PENISDecember 2021November 2025Allow4741YesNo
17561504Urinary Drainage System with Air Pressure ApparatusDecember 2021January 2024Allow2530NoYes
17559096HAND CONTAMINATION PREVENTING DRAINAGE BAG STRUCTUREDecember 2021October 2023Abandon2210NoNo
17556942Dynamic Pressure Response System and Method for Measuring Residual FluidDecember 2021June 2024Allow3040YesNo
17615924PRESSURE-MEASURING ASSEMBLY FOR AN EXTRACORPOREAL BLOOD TREATMENT MACHINEDecember 2021May 2025Abandon4120NoNo
17613400CONTROL SYSTEMNovember 2021July 2025Abandon4420NoNo
17613456SYSTEMS AND METHODS FOR EXTENDING OPERATIONAL TIME OF NEGATIVE PRESSURE WOUND TREATMENT APPARATUSESNovember 2021January 2024Allow2610YesNo
17609281BLOOD ANALYSIS SYSTEMNovember 2021March 2025Allow4010NoNo
17609218EMPTYING A BLOOD CIRCUIT AFTER EXTRACORPOREAL BLOOD TREATMENTNovember 2021July 2025Allow4420NoNo
17287046SYSTEM, COMPUTER SYSTEM AND COMPUTER PROGRAM FOR DETERMINING A CARDIOVASCULAR PARAMETERNovember 2021November 2024Allow4320YesNo
17606881MEDICAL FLUID TRANSFER APPARATUSOctober 2021November 2024Allow3720YesNo
17448811FLUID COLLECTION SYSTEMS INCLUDING AT LEAST ONE TENSIONING ELEMENTSeptember 2021June 2024Allow3330YesNo
17480619ADJUSTABLE OUTER COVER FOR TWO PIECE ABSORBENT ARTICLESeptember 2021June 2024Abandon3221NoNo
17440008GARMENT INCLUDING A MICRO-PUMP FOR NON-FLUID MANAGEMENT TISSUE THERAPIESSeptember 2021May 2025Abandon4441NoNo
17471488INTEGRATED PORTABLE APPARATUS FOR TOPICAL WOUND THERAPY, USING AMBIENT AIR FOR THE CREATION OF THREE BIOACTIVE GASES THAT INDEPENDENTLY AND SYNERGISTICALLY ASSIST IN THE RESOLUTION OF PATHOGENIC DERMATOLOGICAL CONDITIONSSeptember 2021September 2023Abandon2410NoNo
17446246SYSTEMS AND METHODS INCLUDING A MALE FLUID COLLECTION DEVICE AND A SECUREMENT ELEMENTAugust 2021August 2023Abandon2401NoNo
17446251SYSTEMS AND METHODS INCLUDING A MALE FLUID COLLECTION DEVICE AND A SECUREMENT ELEMENTAugust 2021August 2023Abandon2401NoNo
17459845Compositions, Dispensers, and Methods Thereof for Establishing a Urine Passageway Through a UreterAugust 2021March 2025Allow4221YesNo
17433769STERILE AZTREONAM PACKAGEAugust 2021December 2024Allow3931NoYes
17410132ABSORBENT ARTICLE WITH CONDUCTIVE MATERIAL ON TWO LAYERSAugust 2021October 2023Abandon2640NoNo
17409453DEVICE FOR IN-FLIGHT URINE ELIMINATIONAugust 2021September 2023Abandon2511NoNo
17408396WEARABLE SYSTEM AND METHOD FOR MODIFICATION OF FLUID ENVIRONMENT OF AN EARAugust 2021July 2024Abandon3511NoNo
17422325CONTROL ALGORITHM FOR NEGATIVE PRESSURE WOUND THERAPY DEVICESJuly 2021July 2024Abandon3620NoNo
17357580CHEM-O-PORT COVERJune 2021May 2024Abandon3520NoNo
17341697ARTICLE HAVING A BOND PATTERNJune 2021January 2026Allow5640NoYes
17339464PRESSURE CONTROL APPARATUSJune 2021December 2024Allow4310NoNo
17309535Blood filtration systemsJune 2021October 2024Allow4010NoNo
17335525DISPOSABLE DIAPERJune 2021March 2025Allow4520YesNo
17298358DEVICES FOR TOPICAL DELIVERY OF ACTIVE AGENTS TO A TARGET SITEMay 2021September 2024Abandon4020NoNo
17325260ABSORBENT ARTICLES HAVING LAMINATES EXHIBITING VIBRANT GRAPHICS PERCEPTIONMay 2021March 2026Abandon5780NoNo
17295101TRANSDERMAL SYSTEM WITH OVERPLASTER AND RING SYSTEMMay 2021June 2025Abandon4921NoNo
17292469INTRAUTERINE EXPANDER DEVICEMay 2021December 2023Abandon3210NoNo
17315925FOOD ARRANGEMENTMay 2021April 2025Abandon4720NoNo
17234765Undergarment for Colostomy PatientsApril 2021April 2024Abandon3520YesNo
17229114MULTI-FUNCTION IRRIGATION-ASPIRATION TUBING FOR OCULAR SURGERY DEVICESApril 2021February 2024Abandon3420NoNo
17281999SCREEN EXCHANGE DEVICE, BIOLOGICAL TISSUE SIZE REDUCTION SYSTEM COMPRISING SAME, BIOLOGICAL TISSUE SIZE REDUCTION METHOD USING SAME, AND METHOD FOR SEPARATING TARGET SUBSTANCE FROM RELEVANT BIOLOGICAL TISSUEApril 2021November 2024Allow4310NoNo
17280109OPTICAL FIBERS FOR OPTICALLY SENSING THROUGH WOUND DRESSINGSMarch 2021November 2024Allow4340YesNo
17277128WIRELESS SYSTEM TO ENABLE AUTO-DETERMINATION OF APPLICATION SPECIFIC THERAPY DEVICE SCREENS AND SETTING OPTIONSMarch 2021April 2025Allow4830NoNo
17202608THREE DIMENSIONAL NONWOVEN AND ABSORBENT ARTICLES HAVING THE SAMEMarch 2021January 2025Allow4630NoNo
17275326ARTERIOVENOUS GRAFT SYSTEM, ARTERIOVENOUS VALVE DEVICE AND METHOD TO IMPLANT AN ARTERIOVENOUS GRAFT SYSTEMMarch 2021May 2024Allow3810NoNo
17175568EVERSIBLE CATHETER WITH MINIMAL RUBBING FRICTIONFebruary 2021March 2023Allow2510YesNo
17174457VARIABLE PARTICLE SIZE TISSUE COLLECTORFebruary 2021August 2023Allow3030YesNo
17173471ABSORBENT ARTICLE WITH FASTENING SYSTEMFebruary 2021September 2025Abandon5660NoNo
17159462DURABLE ABSORBENT PANTJanuary 2021May 2025Allow5250YesNo
17151598Urinary Catheter Suited for Hyperbaric Oxygen Therapy for ProstatitisJanuary 2021December 2023Abandon3520NoNo
17151107CVC LINE BLOOD DRAWING METHODJanuary 2021November 2024Abandon4620NoNo
17258833FEMALE-FEMALE ADAPTERJanuary 2021January 2025Allow4831YesNo
17138002CATHETERS WITH SHAPE LOCKING MECHANISMSDecember 2020December 2023Allow3540YesNo
17113333FLEXIBLE AND COMPLIANT MECHANICALLY-DEFORMED NONWOVENS FOR USE IN ABSORBENT ARTICLESDecember 2020August 2025Abandon5650NoNo
17093102Blood Treatment SystemsNovember 2020December 2024Allow4950NoNo
17048354THIN FLUID ABSORBENT CORE-ABSORBENT PAPEROctober 2020February 2025Allow5240NoNo
17034850EPIDERMAL SUSPENSION SPRAY DEVICESeptember 2020December 2024Abandon5110NoNo
16978971Methods, Materials, Devices and Systems for Treating Injuries to Central Nervous SystemSeptember 2020September 2024Abandon4820NoNo
16970788SYSTEMS AND METHODS FOR TRAUMA-FREE APPLICATION AND REMOVAL OF LIGHT DEACTIVATED ADHESIVE DRAPESAugust 2020April 2024Allow4410NoNo
16968435METHOD AND SYSTEM FOR MONITORING CARBON MONOXIDE (CO) ADMINISTRATION TO EX-VIVO FLUIDSAugust 2020August 2024Abandon4801NoNo
16983385SURGICAL SAFETY TOWELAugust 2020March 2024Abandon4310NoNo
16944642Weight Loss Devices Having Anchor-Free RegionsJuly 2020June 2024Abandon4710NoNo
16964780PEN NEEDLE COVERJuly 2020April 2024Abandon4510NoNo
16963567WETNESS INDICATING COMPOSITIONS INCLUDING AN AMPHIPHILIC POLYDIACETYLENE AND ABSORBENT ARTICLES INCLUDING THE SAMEJuly 2020November 2024Abandon5220NoNo
16961440MODULAR EXTRACORPOREAL AMBULATORY LUNG ASSIST DEVICEJuly 2020October 2024Allow5130YesNo
16955636COMPOSITE WEBSJune 2020May 2024Abandon4710NoNo
16636863ELASTIC MEMBER AND DISPOSABLE WEARING ARTICLE INCLUDING ELASTIC MEMBERFebruary 2020February 2026Allow6060YesNo
16626039ABSORBENT ARTICLE AND METHOD FOR MANUFACTURING AN ABSORBENT ARTICLEDecember 2019June 2024Allow5320YesYes
16620764UNDERPANTS-TYPE DISPOSABLE DIAPERDecember 2019August 2024Abandon5620YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PHAM, KATHERINE-PH MINH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
99.4%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
2
(50.0%)
Not Allowed After Appeal Filing
2
(50.0%)
Filing Benefit Percentile
84.0%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner PHAM, KATHERINE-PH MINH - Prosecution Strategy Guide

Executive Summary

Examiner PHAM, KATHERINE-PH MINH works in Art Unit 3781 and has examined 64 patent applications in our dataset. With an allowance rate of 48.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner PHAM, KATHERINE-PH MINH's allowance rate of 48.4% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PHAM, KATHERINE-PH MINH receive 2.36 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PHAM, KATHERINE-PH MINH is 43 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +58.4% benefit to allowance rate for applications examined by PHAM, KATHERINE-PH MINH. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.4% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.0% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 150.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 90% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 133.3% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.